Fibromyalgia – Pipeline Review, Q1 2011
Fibromyalgia - Pipeline Review, Q1 2011
Reference Code: GMDHC058IDB
Publication Date: February 2011
Fibromyalgia – Pipeline Review, Q1 2011 GMDHC058IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Fibromyalgia – Pipeline Review, Q1 2011
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables ............................................................................................................................................................................................................ 4
List of Figures ........................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Fibromyalgia Overview ............................................................................................................................................................................................. 6
Therapeutics Development ....................................................................................................................................................................................... 7
An Overview of Pipeline Products for Fibromyalgia ............................................................................................................................................ 7
Fibromyalgia Therapeutics under Development by Companies ................................................................................................................................ 9
Fibromyalgia Therapeutics under Investigation by Universities/Institutes .................................................................................................................11
Late Stage Products ................................................................................................................................................................................................12
Comparative Analysis .......................................................................................................................................................................................12
Mid Clinical Stage Products .....................................................................................................................................................................................13
Comparative Analysis .......................................................................................................................................................................................13
Early Clinical Stage Products ..................................................................................................................................................................................14
Comparative Analysis .......................................................................................................................................................................................14
Pre-Clinical Stage Products .....................................................................................................................................................................................15
Comparative Analysis .......................................................................................................................................................................................15
Companies Involved in Fibromyalgia Therapeutics Development ............................................................................................................................16
Boehringer Ingelheim GmbH .............................................................................................................................................................................16
Meda AB ...........................................................................................................................................................................................................16
UCB Group .......................................................................................................................................................................................................17
Jazz Pharmaceuticals, Inc. ................................................................................................................................................................................17
Chelsea Therapeutics, Inc. ................................................................................................................................................................................18
e-Therapeutics plc.............................................................................................................................................................................................18
Rottapharm SpA ...............................................................................................................................................................................................19
Sosei Co. Ltd. ...................................................................................................................................................................................................19
SWITCH Biotech LLC .......................................................................................................................................................................................20
Universities/Institutes Involved in Fibromyalgia Therapeutics Development .............................................................................................................21
Fibromyalgia - Therapeutics Assessment ................................................................................................................................................................22
Assessment by Monotherapy Products .............................................................................................................................................................22
Assessment by Route of Administration ............................................................................................................................................................23
Assessment by Molecule Type ..........................................................................................................................................................................25
Late Stage Drug Profiles – Companies ....................................................................................................................................................................27
JZP-6 - Drug Profile ..........................................................................................................................................................................................27
Product Description ....................................................................................................................................................................................27
Mechanism of Action...................................................................................................................................................................................27
R&D Progress .............................................................................................................................................................................................27
Late Stage Drug Profiles – Universities/Institutes ....................................................................................................................................................28
Amitryptiline - Drug Profile.................................................................................................................................................................................28
Product Description ....................................................................................................................................................................................28
Mechanism of Action...................................................................................................................................................................................28
R&D Progress .............................................................................................................................................................................................28
Anzemet - Drug Profile ......................................................................................................................................................................................29
Product Description ....................................................................................................................................................................................29
Mechanism of Action...................................................................................................................................................................................29
R&D Progress .............................................................................................................................................................................................29
Fibromyalgia – Pipeline Review, Q1 2011 GMDHC058IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Fibromyalgia – Pipeline Review, Q1 2011
Armodafinil - Drug Profile .........................................................................................................................................